Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Operation Sindoor highlighted the deepening military cooperation between Pakistan and China, prompting India to consider increasing its defense budget to 2.5% of GDP. The focus should be on self ...

The NFL star made the revelation during a press conference on Tuesday. The NFL star made the revelation during a press conference on Tuesday. Gauff, the 2025 French Open champion, comes from a ...